Introduction to
FFPE Samples with Genomic and Proteomic Characterization
Genomically and Proteomically Characterized FFPE Tumor Samples
Genomic and proteomic characterization provides complementary information about the molecular state of a tumor. Genomic data can identify mutations, amplifications, deletions and other DNA-level alterations, while proteomic measurements can reveal changes in protein abundance, pathway activity and biomarker expression. FFPE tumor samples containing both types of information allow researchers to investigate whether genomic alterations lead to corresponding functional changes at the protein level. These biospecimens are especially valuable for proteogenomic research, biomarker discovery and targeted-therapy development. Researchers can use them to explore signaling pathways, identify biologically relevant molecular subtypes and investigate potential mechanisms of treatment resistance. Because FFPE tissue preserves histological architecture, molecular findings can also be related directly to tumor morphology and microenvironmental features.
Proteogenomic FFPE Biospecimens for Biomarker Discovery
Proteogenomics combines genomic and protein-level data to provide a broader understanding of cancer biology. FFPE samples with these matched datasets can support discovery of biomarkers that are not evident from DNA analysis alone. For example, a genomic alteration may be present without meaningful downstream protein activation, while changes in protein expression may occur through mechanisms not captured by routine sequencing. By analyzing both layers together, researchers can identify more biologically informative signatures and potentially improve patient stratification strategies.
Â
Such specimens can also help validate protein biomarkers associated with specific genomic subgroups. When pathology and clinical data are available, researchers can further explore how proteogenomic patterns relate to histological subtype, disease progression and therapeutic response.
Genomic and Protein Data for Oncology Drug-Development Programs
Drug developers increasingly need to understand both the molecular alterations present in a tumor and the functional state of the pathways those alterations affect. FFPE samples containing genomic and proteomic characterization provide an integrated resource for studying potential therapeutic targets and resistance mechanisms. Researchers can identify tumors with specific mutations or amplifications and then evaluate downstream protein-expression or signaling patterns.
These data can support hypothesis generation for targeted therapies, combination strategies and biomarker-defined clinical-development programs. Proteogenomic cohorts may also help identify subgroups that appear molecularly similar at the DNA level but differ significantly in functional protein activity. This type of integrated analysis can strengthen translational research and improve understanding of the biological context surrounding potential drug targets.
Data-Rich FFPE Samples for Computational and AI Research
Artificial-intelligence models can become more informative when trained using multiple biological data types. FFPE samples with matched genomic and proteomic information can support development of multimodal algorithms that integrate digital pathology with molecular characteristics. Researchers may train models to predict genomic alterations, protein-expression states or pathway activity directly from H&E morphology. Such datasets can also support computational discovery of relationships between histological patterns and molecular phenotypes that may not be apparent through conventional analysis. When clinical annotation is included, AI systems can potentially incorporate patient and disease characteristics into broader predictive frameworks. Genomically and proteomically characterized FFPE specimens therefore provide a strong foundation for computational pathology, precision-oncology and drug-response research.
General Questions
Frequent Asked Questions!!
FFPE blocks for genomics are formalin-fixed, paraffin-embedded tissue samples used for DNA, RNA, and biomarker analysis. They are widely used in cancer genomics, molecular pathology, translational research, and retrospective studies.
FFPE tissue blocks are valuable because they preserve tissue architecture and molecular material for long-term storage. Researchers can use them for sequencing, mutation analysis, biomarker discovery, and validation studies.
Yes. DNA can be extracted from FFPE blocks using validated extraction kits and optimized laboratory protocols. DNA quality depends on fixation time, block age, tissue type, tumor content, and storage conditions.
Yes. RNA can be extracted from FFPE tissue, although it is often fragmented because of formalin fixation. Specialized FFPE RNA extraction methods can provide material suitable for targeted RNA sequencing, gene expression studies, and fusion analysis.
Yes. High-quality FFPE blocks are commonly used for next-generation sequencing, including targeted sequencing panels, whole-exome sequencing, RNA sequencing, and selected whole-genome applications.
Tumor content requirements depend on the study design and testing method. Many molecular and NGS studies require at least 20% tumor content, while some projects may require 30%, 50%, or higher tumor percentage. Pathologist review can be performed to confirm tumor content before shipment
FFPE blocks can support mutation testing, copy number analysis, gene fusion detection, microsatellite instability testing, tumor mutational burden analysis, methylation studies, and targeted DNA or RNA sequencing.
Yes. FFPE cancer tissue blocks are extensively used to study genomic alterations in lung, breast, colorectal, prostate, ovarian, pancreatic, liver, kidney, and other tumor types.
Researchers can purchase FFPE blocks from qualified biospecimen suppliers, biobanks, pathology laboratories, hospitals, and research networks that provide ethically sourced and clinically annotated human tissue samples.
Researchers should confirm diagnosis, tissue type, tumor percentage, necrosis percentage, fixation details, block age, specimen size, available clinical data, pathology review, consent status, and intended research-use permissions.
Yes. Clinically annotated FFPE blocks may include donor age, sex, diagnosis, grade, stage, TNM classification, treatment history, pathology report, mutation status, and clinical outcome data.